Boehringer Ingelheim (BI) has announced in a 

 the expansion of its biopharmaceutical manufacturing  capabilities at its plants in Biberach, Germany and in Vienna, Austria.

  The expansion will include cell-culture and microbial-fermentation capacity  and support cell-line and process-development services for BI’s contract  manufacturing business. BI has invested approximately EUR 17 million ($26.8  million) to expand cGMP cell banking, process science, cell-line development,  and quality laboratories at the two sites.

  BI expects to use the expanded resources for services that include  monoclonal antibody development, product development using BI’s proprietary  high-expression systems, and proprietary plasmid DNA platform. In addition, the  facilities will support collaborations with Pfenex on 

 bacterial expression technology and with VTU Technology on 

  In the company release, Dr. Dorothee Ambrosius, senior vice-president of  Biopharmaceuticals Global Process Science, says, “This is another milestone  within our contract manufacturing strategy securing technology leadership and  towards increased flexibility and customer orientation.”

News

Boehringer Ingelheim (BI) has announced in a press release the expansion of its biopharmaceutical manufacturing capabilities at its plants in Biberach, Germany and in Vienna, Austria.